(AVXL) Anavex Life Sciences - Ratings and Ratios
Alzheimers, Parkinsons, Rett Syndrome, Schizophrenia, Cancer
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 88.0% |
| Value at Risk 5%th | 114% |
| Relative Tail Risk | -21.47% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.01 |
| Alpha | -86.35 |
| CAGR/Max DD | -0.36 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.565 |
| Beta | 1.134 |
| Beta Downside | 0.508 |
| Drawdowns 3y | |
|---|---|
| Max DD | 77.12% |
| Mean DD | 39.13% |
| Median DD | 35.88% |
Description: AVXL Anavex Life Sciences November 30, 2025
Anavex Life Sciences Corp. (NASDAQ:AVXL) is a U.S.-based biopharma focused on developing oral small-molecule therapeutics that modulate the sigma-1 receptor (SIGMAR1) and muscarinic pathways to restore cellular homeostasis in central-nervous-system (CNS) disorders.
The company’s lead candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a trial and is currently in a combined Phase 2b/3 study for Alzheimer’s disease, a Phase 2 proof-of-concept trial for Parkinson’s disease dementia, and Phase 2/3 programs in Rett syndrome (adult and pediatric cohorts). A separate SIGMAR1/M1-targeting molecule, ANAVEX 3-71, shows disease-modifying activity in transgenic Alzheimer’s mouse models, reducing amyloid, tau, and cognitive deficits. All programs are oral, which could simplify dosing compared with biologics.
As of the latest filing (Q2 2025), AVXL reported a cash runway of roughly 18 months and a market capitalization near $150 million, placing it in the micro-cap segment where financing risk is material. The CNS biotech sector is projected to grow at a CAGR of ~9 % through 2030, driven by an aging population and unmet therapeutic needs in neurodegeneration; however, the company’s valuation is highly sensitive to the upcoming Phase 2b/3 readout for Alzheimer’s disease, which is expected in early 2026. For a deeper quantitative assessment, the ValueRay platform provides an up-to-date analyst model you may wish to review.
Piotroski VR‑10 (Strict, 0-10) 0.0
| error: Net Income check cannot be calculated (needs Net Income TTM and Revenue TTM) |
| FCFTA -0.38 (>2.0%) and ΔFCFTA -14.88pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.38 (>3.0%) and CFO -39.0m > Net Income -46.4m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 11.60 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (86.7m) change vs 12m ago 3.17% (target <= -2.0% for YES) |
| error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue) |
| Asset Turnover 0.0% (prev 0.0%; Δ 0.0pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -1.03 (EBITDA TTM -23.7m / Interest Expense TTM 23.2m) >= 6 (WARN >= 3) |
Altman Z'' -52.24
| (A) 0.91 = (Total Current Assets 103.8m - Total Current Liabilities 8.95m) / Total Assets 103.8m |
| (B) -3.68 = Retained Earnings (Balance) -382.4m / Total Assets 103.8m |
| warn (B) unusual magnitude: -3.68 — check mapping/units |
| (C) -0.20 = EBIT TTM -23.8m / Avg Total Assets 119.7m |
| (D) -42.75 = Book Value of Equity -382.4m / Total Liabilities 8.95m |
| Total Rating: -52.24 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 25.42
| 1. Piotroski 0.0pt |
| 2. FCF Yield -18.12% |
| 3. FCF Margin data missing |
| 4. Debt/Equity data missing |
| 5. Debt/Ebitda 4.33 |
| 6. ROIC - WACC (= -29.21)% |
| 7. RoE -46.79% |
| 8. Revenue Trend data missing |
| 9. EPS Trend 58.38% |
What is the price of AVXL shares?
Over the past week, the price has changed by +15.17%, over one month by -5.53%, over three months by -58.08% and over the past year by -69.54%.
Is AVXL a buy, sell or hold?
- Strong Buy: 2
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the AVXL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 22 | 415.2% |
| Analysts Target Price | 22 | 415.2% |
| ValueRay Target Price | 3.3 | -22.7% |
AVXL Fundamental Data Overview January 09, 2026
P/E Forward = 3.8521
P/B = 3.5789
Beta = 1.154
Revenue TTM = 0.0 USD
EBIT TTM = -23.8m USD
EBITDA TTM = -23.7m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = -102.6m USD (from netDebt column, last fiscal year)
Enterprise Value = 215.5m USD (318.1m + (null Debt) - CCE 102.6m)
Interest Coverage Ratio = -1.03 (Ebit TTM -23.8m / Interest Expense TTM 23.2m)
FCF Yield = -18.12% (FCF TTM -39.0m / Enterprise Value 215.5m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 52.0m) / Revenue TTM)
Tobins Q-Ratio = 2.08 (Enterprise Value 215.5m / Total Assets 103.8m)
Interest Expense / Debt = unknown (Interest Expense 23.2m / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = -18.8m (EBIT -23.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 11.60 (Total Current Assets 103.8m / Total Current Liabilities 8.95m)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = 4.33 (negative EBITDA) (Net Debt -102.6m / EBITDA -23.7m)
Debt / FCF = 2.63 (negative FCF - burning cash) (Net Debt -102.6m / FCF TTM -39.0m)
Total Stockholder Equity = 99.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -44.67% (Net Income -46.4m / Total Assets 103.8m)
RoE = -46.79% (Net Income TTM -46.4m / Total Stockholder Equity 99.1m)
RoCE = -25.10% (EBIT -23.8m / Capital Employed (Total Assets 103.8m - Current Liab 8.95m))
RoIC = -18.98% (negative operating profit) (NOPAT -18.8m / Invested Capital 99.1m)
WACC = 10.23% (E(318.1m)/V(318.1m) * Re(10.23%) + (debt-free company))
Discount Rate = 10.23% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.76%
Fair Price DCF = unknown (Cash Flow -39.0m)
EPS Correlation: 58.38 | EPS CAGR: 40.64% | SUE: 4.0 | # QB: 2
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.12 | Chg30d=+0.015 | Revisions Net=+1 | Analysts=2
EPS current Year (2026-09-30): EPS=-0.48 | Chg30d=+0.047 | Revisions Net=+0 | Growth EPS=+11.1% | Growth Revenue=+0.0%
EPS next Year (2027-09-30): EPS=1.27 | Chg30d=+0.020 | Revisions Net=-1 | Growth EPS=+364.6% | Growth Revenue=+0.0%
Additional Sources for AVXL Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle